Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Hepatitis C virus | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0084 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0084 | 1 | 1 |
Toxoplasma gondii | deoxyhypusine synthase | 0.007 | 0.6724 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0084 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0084 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0084 | 1 | 1 |
Schistosoma mansoni | deoxyhypusine synthase | 0.007 | 0.6724 | 0.6724 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0074 | 0.7743 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0052 | 0.2407 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0084 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0084 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0084 | 1 | 1 |
Echinococcus multilocularis | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Entamoeba histolytica | deoxyhypusine synthase, putative | 0.007 | 0.6724 | 0.5 |
Echinococcus granulosus | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0084 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0084 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0084 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0042 | 0.0151 | 0.0151 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0084 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0084 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0084 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0084 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0084 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0084 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0074 | 0.7743 | 0.3111 |
Leishmania major | cytochrome P450 reductase, putative | 0.0074 | 0.7743 | 0.3111 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0074 | 0.7743 | 0.3111 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0074 | 0.7743 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0084 | 1 | 1 |
Loa Loa (eye worm) | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Entamoeba histolytica | deoxyhypusine synthase, putative | 0.007 | 0.6724 | 0.5 |
Brugia malayi | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0052 | 0.2407 | 0.2407 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 261 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
EC50 (functional) | = 261 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
EC90 (functional) | = 4953 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
EC90 (functional) | = 4953 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
IC50 (binding) | = 20 nM | Inhibitory activity against HCV delta 21 NS5B RNA polymerase by SPA assay | ChEMBL. | 16451063 |
IC50 (binding) | = 20 nM | Inhibitory activity against HCV delta 21 NS5B RNA polymerase by SPA assay | ChEMBL. | 16451063 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.